| A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) |
Ongoing |
MEDI4736+Tremelimumab |
3 |
D419AC00003 |
King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam) |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer |
Ongoing |
MEDI4736/Paclitaxel |
2 |
ESR-14-10649 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| RIFTOS MKI - Radioactive Iodine reFractory asymptomatic patients in differentiated Thyroid cancer – an Observational Study to assess the use of MultiKinase Inhibitors |
Ongoing |
Nexavar (Sorafenib) |
4 |
17852 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Randomized, three- way, three- period, single oral dose, open-label, crossover, bioequivalence study to compare Lorvast Tablets /Tabuk Pharmaceutical Mfg. Co. (20 mg Atorvastatin), versus Lipitor® (20 mg Atorvastatin) Produced by Pfizer in healthy subjects under fasting conditions. |
Completed |
Lipitor® lovarst tablet |
4 |
42370 |
saudi Ajal |
| SAUDI ARABIA – A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
Ongoing |
N/A |
4 |
ML29618 |
King Abdulaziz Medical City NG (Riyadh) |
| Treatment Patterns, Outcomes, and Resource Use Study For Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-Squamous)in Kingdom of Saudi Arabia and United Arab Emirates |
Ongoing |
- |
4 |
CA209454 |
King Abdulaziz Medical City NG (Riyadh) |
| Phase III, Double-Blind, Placebo-Controlled Study Of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With Or Without Nimotuzumab For Stage III/IV Head And Neck Squamous Cell Cancer |
Ongoing |
Nimotuzumab |
3 |
1HN01 |
King Fahad Medical City (Riyadh) |
| The study of efficacy and saftey of Rituximab in treatment of resistant glomerulonephritis |
Ongoing |
Rituximab |
3 |
MN-101-11 |
King Fahad Medical City (Riyadh), King Abdulaziz Hospital and Oncology Center (Jeddah), Dammam Medical Complex, King Fahad Hospital (Jeddah), Armed Forces Hospital (Al-Hada), Armed Forces Hospital (Southern Region), King Fahad University Hospital (Al-Khobar), King Fahd Armed Forces Hospital (Jeddah) |
| Treatment of Neuroendocrine Tumors (NETs) with combination of Everolimus and Radiolabeld Somatostatin Analogue |
Ongoing |
Everolimus |
2 |
ONC-CRC 12- 12 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Circulating Endotoxin as a Contributing Inflammatory Mediator in Osteoporosis Risk and its Association with Vitamin D Deficiency |
Ongoing |
Vitamin D3 / Alendronate |
3 |
11-MED-2113-02 |
Ministry of Health |
